國家衛健委:河北、江蘇、安徽、廣東、福建、浙江、山東等省疫情總體可控
格隆匯4月12日丨國務院聯防聯控機制舉行新聞發佈會。會上,國家衛生健康委疾控局副局長、一級巡視員雷正龍介紹,3月1日—4月11日,31個省(自治區、直轄市)和新疆生產建設兵團累計報告本土感染者325303例,波及30個省(區、市),隨着各地疫情防控措施的落實落地,新發生疫情的地區能夠快速有效處置,未形成新的規模性疫情。河北、江蘇、安徽、廣東、福建、浙江、山東等省疫情總體可控。吉林省疫情總體呈下降態勢,已連續3天新增感染者降至千例以下,但仍在高位;長春市每日新增感染者人數下降,但管控區內社區傳播未完全阻斷,仍需繼續加強管控區內各項防控工作。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.